Analysis reveals survival trends with pde5 inhibitors in pulmonary hypertension from interstitial lung disease, suggesting potential treatment benefits.
"A 10,000-Foot View at Survival and Treatment with PDE5 Inhibitors in Interstitial Lung Disease Pulmonary Hypertension." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
No takes yet. Share an insight, caveat, or question.
Shlobin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: